AAUM (Average Assets Under Management) of ₹84.60 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 62.5% | 62.6% | ● +0.1% |
| Healthcare Services | 27.1% | 29.1% | ▲ +2.0% |
| Chemicals & Petrochemicals | 5.6% | 5.2% | ▼ -0.4% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 62.6% | 62.7% | ▲ +0.1% |
| Healthcare Services | 29.1% | 30.1% | ▲ +1.0% |
| Chemicals & Petrochemicals | 5.2% | 5.7% | ▲ +0.5% |
Comparing Jul 2026 → Aug 2026
| # | Stock | Sector | Weight (Aug 2026) |
|---|---|---|---|
| 1 | Syngene International Limited ₹1.00 Cr |
Healthcare Services | 0.97% |
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Neuland Laboratories Limited ₹6.58 Cr |
Pharmaceuticals & Biotechnology | 5.57% | 6.38% | +0.81% |
| 2 | Dr Agarwals Health Care Limited ₹2.62 Cr |
Healthcare Services | 1.94% | 2.54% | +0.60% |
| 3 | Cohance Lifesciences Limited ₹3.01 Cr |
Pharmaceuticals & Biotechnology | 2.37% | 2.92% | +0.55% |
| 4 | Navin Fluorine International Limited ₹5.83 Cr |
Chemicals & Petrochemicals | 5.20% | 5.65% | +0.45% |
| 5 | Metropolis Healthcare Limited ₹3.27 Cr |
Healthcare Services | 2.82% | 3.17% | +0.35% |
| 6 | Gland Pharma Limited ₹4.05 Cr |
Pharmaceuticals & Biotechnology | 3.60% | 3.93% | +0.33% |
| 7 | IPCA Laboratories Limited ₹3.28 Cr |
Pharmaceuticals & Biotechnology | 2.97% | 3.18% | +0.21% |
| 8 | Aurobindo Pharma Limited ₹5.33 Cr |
Pharmaceuticals & Biotechnology | 5.02% | 5.17% | +0.15% |
| 9 | Aster DM Healthcare Limited ₹4.97 Cr |
Healthcare Services | 4.67% | 4.82% | +0.15% |
| 10 | Glenmark Pharmaceuticals Limited ₹2.97 Cr |
Pharmaceuticals & Biotechnology | 2.74% | 2.88% | +0.14% |
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited ₹10.41 Cr |
Pharmaceuticals & Biotechnology | 10.69% | 10.09% | -0.60% |
| 2 | Torrent Pharmaceuticals Limited ₹6.65 Cr |
Pharmaceuticals & Biotechnology | 6.89% | 6.45% | -0.44% |
| 3 | Apollo Hospitals Enterprise Limited ₹6.42 Cr |
Healthcare Services | 6.62% | 6.23% | -0.39% |
| 4 | Fortis Healthcare Limited ₹3.90 Cr |
Healthcare Services | 4.16% | 3.78% | -0.38% |
| 5 | Max Healthcare Institute Limited ₹2.63 Cr |
Healthcare Services | 2.84% | 2.55% | -0.29% |
| 6 | Onesource Specialty Pharma Limited ₹2.28 Cr |
Pharmaceuticals & Biotechnology | 2.49% | 2.21% | -0.28% |
| 7 | Mankind Pharma Limited ₹2.98 Cr |
Pharmaceuticals & Biotechnology | 3.12% | 2.89% | -0.23% |
| 8 | Biocon Limited ₹2.62 Cr |
Pharmaceuticals & Biotechnology | 2.77% | 2.54% | -0.23% |
| 9 | Divi's Laboratories Limited ₹9.58 Cr |
Pharmaceuticals & Biotechnology | 9.47% | 9.29% | -0.18% |
| 10 | Zydus Lifesciences Limited ₹4.94 Cr |
Pharmaceuticals & Biotechnology | 4.90% | 4.79% | -0.11% |
23 stocks — Aug 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹10.41 Cr |
Pharmaceuticals & Biotechnology |
10.09%
|
|
| 2 |
₹9.58 Cr |
Pharmaceuticals & Biotechnology |
9.29%
|
|
| 3 |
₹6.65 Cr |
Pharmaceuticals & Biotechnology |
6.45%
|
|
| 4 |
₹6.58 Cr |
Pharmaceuticals & Biotechnology |
6.38%
|
|
| 5 |
₹6.42 Cr |
Healthcare Services |
6.23%
|
|
| 6 |
₹5.83 Cr |
Chemicals & Petrochemicals |
5.65%
|
|
| 7 |
₹5.33 Cr |
Pharmaceuticals & Biotechnology |
5.17%
|
|
| 8 |
₹4.97 Cr |
Healthcare Services |
4.82%
|
|
| 9 |
₹4.94 Cr |
Pharmaceuticals & Biotechnology |
4.79%
|
|
| 10 |
₹4.05 Cr |
Pharmaceuticals & Biotechnology |
3.93%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.